Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.
Fiche publication
Date publication
octobre 2016
Journal
Expert opinion on biological therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Pouillon L, Bossuyt P, Peyrin-Biroulet L
Lien Pubmed
Résumé
Crohn's disease (CD) and ulcerative colitis (UC) are chronic disabling conditions. Monoclonal antibody therapy directed against tumor necrosis factor-alpha (anti-TNF) has revolutionized the care of patients with inflammatory bowel disease (IBD).
Mots clés
Adalimumab, Crohn’s disease, TNF antagonists, anti-TNF, biosimilar, certolizumab pegol, combination therapy, golimumab, inflammatory bowel disease, infliximab, personalized medicine, pharmacogenomics, tailored therapy, therapeutic drug monitoring, ulcerative colitis
Référence
Expert Opin Biol Ther. 2016 10;16(10):1277-90